Gut bacteria boosts breast cancer treatment? new trial launches

NCT ID NCT07552181

First seen Apr 29, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding a live bacteria supplement (MO-03) to standard chemotherapy and immunotherapy (pembrolizumab) can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants take the supplement twice daily until surgery, then are followed for 5 years. The main goal is to see if the combination leads to no cancer remaining at surgery (pathological complete response).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CS Cancer at Valley Oncology Medical Group

    Tarzana, California, 91356, United States

    Contact

    Contact

    Contact

  • Cedars-Sinai Medical Center Beverly Hills

    Beverly Hills, California, 90211, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

  • Hunt Cancer Institute, an Affiliate of CS Cancer

    Torrance, California, 90505, United States

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.